tradingkey.logo

UCB Says Its DZP Shows 'Efficacy' Across Multiple Clinical Endpoints

ReutersJun 12, 2025 5:13 AM

- UCB SA UCB.BR:

  • DAPIROLIZUMAB PEGOL PHASE 3 DATA IN SLE PRESENTED AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR) SHOW IMPROVEMENT IN FATIGUE AND REDUCTION IN DISEASE ACTIVITY

  • DZP SHOWED CONSISTENT IMPROVEMENTS IN FATIGUE, A COMMON AND DEBILITATING SYMPTOM OF SYSTEMIC LUPUS ERYTHEMATOSUS

  • DAPIROLIZUMAB PEGOL (DZP) SHOWED EFFICACY ACROSS MULTIPLE CLINICAL ENDPOINTS IN PHOENYCS GO STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI